The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Company profile
Ticker
BMY, CELG-RI
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1096271 BC ULC • 345 Park LLC • 9643435 Canada Inc. • Abraxis BioScience Australia Pty Ltd. • Abraxis BioScience International Holding Company, Inc. • Abraxis BioScience Puerto Rico, LLC • Abraxis BioScience, Inc. • Abraxis BioScience, LLC • AbVitro LLC • Acetylon Pharmaceuticals, Inc. ...
IRS number
220790350
BMY stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
26 Jul 24
8-K
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
26 Jul 24
8-K
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
18 Jun 24
8-K
Amendments to Articles of Incorporation or Bylaws
9 May 24
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
25 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
Transcripts
BMY
Earnings call transcript
2024 Q2
26 Jul 24
BMY
Earnings call transcript
2024 Q1
25 Apr 24
BMY
Earnings call transcript
2023 Q4
2 Feb 24
BMY
Earnings call transcript
2023 Q3
26 Oct 23
BMY
Earnings call transcript
2023 Q2
27 Jul 23
BMY
Earnings call transcript
2023 Q2
27 Jul 23
BMY
Earnings call transcript
2023 Q1
27 Apr 23
BMY
Earnings call transcript
2022 Q4
2 Feb 23
BMY
Earnings call transcript
2022 Q3
26 Oct 22
BMY
Earnings call transcript
2022 Q2
27 Jul 22
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 6.30 bn | 6.30 bn | 6.30 bn | 6.30 bn | 6.30 bn | 6.30 bn |
| Cash burn (monthly) | 1.01 bn | 177.42 mm | (no burn) | 532.58 mm | (no burn) | (no burn) |
| Cash used (since last report) | 2.31 bn | 405.54 mm | n/a | 1.22 bn | n/a | n/a |
| Cash remaining | 3.98 bn | 5.89 bn | n/a | 5.08 bn | n/a | n/a |
| Runway (months of cash) | 3.9 | 33.2 | n/a | 9.5 | n/a | n/a |
Institutional ownership, Q2 2024
75.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2097 |
| Opened positions | 204 |
| Closed positions | 360 |
| Increased positions | 658 |
| Reduced positions | 999 |
| 13F shares | Current |
|---|---|
| Total value | 60.14 tn |
| Total shares | 1.53 bn |
| Total puts | 32.05 mm |
| Total calls | 29.55 mm |
| Total put/call ratio | 1.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 186.57 mm | $7.75 tn |
| BLK BlackRock | 158.66 mm | $6.59 tn |
| STT State Street | 91.45 mm | $3.80 tn |
| JPM JPMorgan Chase & Co. | 74.63 mm | $3.10 tn |
| Charles Schwab Investment Management | 59.06 mm | $2.45 tn |
| Capital International Investors | 55.41 mm | $2.30 tn |
| Geode Capital Management | 42.17 mm | $1.75 tn |
| FMR | 40.66 mm | $1.69 tn |
| Norges Bank | 32.59 mm | $1.35 tn |
| MS Morgan Stanley | 26.16 mm | $1.09 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Aug 24 | Cari Gallman | Common Stock, $0.10 par value | Payment of exercise | Dispose F | No | No | 48.17 | 384 | 18.50 k | 2,109 |
| 1 Aug 24 | Cari Gallman | Common Stock, $0.10 par value | Option exercise | Acquire M | No | No | 0 | 1,061 | 0.00 | 2,493 |
| 1 Aug 24 | Cari Gallman | RSU Common Stock, $0.10 par value | Option exercise | Dispose M | No | No | 0 | 1,061 | 0.00 | 2,122 |
| 29 Jul 24 | McMullen Michael R. | Call Option (obligation to sell) Common Stock, $0.10 par value | Other | Dispose J | Yes | No | 46 | 5 | 230.00 | 0 |
| 1 Jul 24 | McMullen Michael R. | Deferred Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 41.3 | 2,986.941 | 123.36 k | 2,986.941 |
News
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
6 Sep 24
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
3 Sep 24
Reported Earlier, Bristol Myers Squibb Presents 3.5-Year Data on CAMZYOS at ESC 2024
3 Sep 24
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
30 Aug 24
Jefferies Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $51
28 Aug 24
Press releases
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
6 Sep 24
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
1 Sep 24
PureTech Health plc – Half-Year Report
28 Aug 24
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
27 Aug 24
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
26 Aug 24